Roche (OTCMKTS:RHHBY) Sets New 52-Week High – Still a Buy?

Roche Holding AG (OTCMKTS:RHHBY)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $60.49 and last traded at $60.4420, with a volume of 243373 shares trading hands. The stock had previously closed at $59.97.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Barclays upgraded shares of Roche from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. TD Cowen reaffirmed a “hold” rating on shares of Roche in a report on Tuesday, February 10th. Finally, Morgan Stanley restated an “underweight” rating on shares of Roche in a research report on Wednesday, February 4th. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $57.00.

Roche Trading Up 0.9%

The firm’s fifty day moving average is $54.75 and its 200-day moving average is $47.49. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Hedge Funds Weigh In On Roche

Several large investors have recently bought and sold shares of the stock. Verity Asset Management Inc. boosted its stake in Roche by 12.5% in the second quarter. Verity Asset Management Inc. now owns 9,092 shares of the company’s stock valued at $371,000 after acquiring an additional 1,008 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Roche by 81.2% during the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after purchasing an additional 826 shares during the last quarter. Everett Harris & Co. CA boosted its position in Roche by 3.5% during the second quarter. Everett Harris & Co. CA now owns 11,190 shares of the company’s stock worth $456,000 after purchasing an additional 381 shares during the period. FineMark National Bank & Trust purchased a new position in shares of Roche in the second quarter worth about $210,000. Finally, Rhumbline Advisers boosted its holdings in Roche by 1.1% in the 2nd quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock worth $4,422,000 after buying an additional 1,228 shares during the period.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.